D9Z Stock Overview
A medical company, operates a network of ophthalmology clinics. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Clínica Baviera, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €35.50 |
| 52 Week High | €39.50 |
| 52 Week Low | €23.40 |
| Beta | 0.69 |
| 1 Month Change | 7.90% |
| 3 Month Change | -0.28% |
| 1 Year Change | 43.15% |
| 3 Year Change | 58.48% |
| 5 Year Change | 178.43% |
| Change since IPO | 54.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| D9Z | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 4.4% | -0.7% | -0.02% |
| 1Y | 43.1% | 38.8% | 15.1% |
Return vs Industry: D9Z exceeded the German Healthcare industry which returned 36.8% over the past year.
Return vs Market: D9Z exceeded the German Market which returned 15.3% over the past year.
Price Volatility
| D9Z volatility | |
|---|---|
| D9Z Average Weekly Movement | 4.4% |
| Healthcare Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D9Z has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: D9Z's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,740 | Eduardo Baviera Sabater | www.clinicabaviera.com |
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, and vías lagrimales treatments.
Clínica Baviera, S.A. Fundamentals Summary
| D9Z fundamental statistics | |
|---|---|
| Market cap | €565.92m |
| Earnings (TTM) | €37.07m |
| Revenue (TTM) | €252.47m |
15.3x
P/E Ratio2.2x
P/S RatioIs D9Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D9Z income statement (TTM) | |
|---|---|
| Revenue | €252.47m |
| Cost of Revenue | €136.51m |
| Gross Profit | €115.96m |
| Other Expenses | €78.89m |
| Earnings | €37.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.32 |
| Gross Margin | 45.93% |
| Net Profit Margin | 14.68% |
| Debt/Equity Ratio | 9.5% |
How did D9Z perform over the long term?
See historical performance and comparisonDividends
4.4%
Current Dividend Yield67%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 07:38 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clínica Baviera, S.A. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ignacio Ortiz de Mendivil | Banco BPI, S.A. |
| León Izuzquiza Lenze | Banco de Sabadell. S.A. |
| Marta Diaz | Banco de Sabadell. S.A. |